Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Christopher, R.; Covington, P.; Davenport, M.; Fleck, P.; Mekki, Q.A.; Wann, E.R.; Karim, A.
    Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects (2008), Clin. Ther., 30, 513-527.
    View publication on PubMed
Search for more literature for 3.4.14.5

Inhibitors

Inhibitors Comment Organism Structure
alogliptin highly selective dipeptidyl peptidase-4 inhibitor, at single doses up to 800 mg alogliptin the mean peak DPP-4 inhibition ranges from 93% to 99% and mean inhibition at 24 hours after dosing ranges from 74% to 97% Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
blood plasma
-
 Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
glucagon-like peptide 1 + H2O
-
 Homo sapiens ?
-
 ?
L-Ala-L-Pro-7-amido-4-methylcoumarin + H2O
-
 Homo sapiens L-Ala-L-Pro + 7-amino-4-methylcoumarin
-
 ?

Synonyms

Synonyms Comment Organism
dipeptidyl peptidase-4
-
 Homo sapiens
DPP-4
-
 Homo sapiens

IC50 Value

IC50 Value IC50 Value Maximum Comment Organism Inhibitor Structure
additional information
-
 50% inhibition of DPP-4 activity is observed at an alogliptin plasma concentration of 3.7 ng/ml Homo sapiens alogliptin